News >

Analysis Confirms Safety of Olaparib in Breast Cancer

Wayne Kuznar
Published: Friday, Jan 05, 2018

Susan M. Domchek, MD
Susan M. Domchek, MD
An analysis of the phase III OlympiAD study presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) showed that treatment discontinuation due to toxicity was less frequent with olaparib (Lynparza) monotherapy compared with chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation.1 Olaparib was well tolerated overall, according to Susan M. Domchek, MD, who presented the findings.

“It’s important that people recognize that nausea, fatigue, and anemia are the 3 major side effects. Nausea can be managed pretty readily by standard antiemetics and, when necessary, dose reduction. You need to let them know it might happen and encourage them to stay on and you get them through it.”
References
  1. Domchek SM, Robson M, Im S-A, Senkus E, et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Presented at: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas. Abstract P5-21-12.
  2. Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523-533.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x